Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4667658 | 0.80 | ALDH1A1 (0.61) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL26091198 | 0.79 | PTPRB (0.49) | ALDH1A1GLAKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL10535687 | 0.79 | ALDH1A1 (0.59) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL4782949 | 0.78 | MEN1 (0.61) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL308738 | 0.76 | ALDH1A1 (0.66) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL2030599 | 0.76 | ALDH1A1 (0.70) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL14831831 | 0.76 | TSHR (0.46) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL21528232 | 0.76 | LTB4R2 (0.50) | POLB | |
| SCHEMBL2754131 | 0.75 | ALDH1A1 (0.54) | ALDH1A1GLATSHRMEN1KMT2A | |
| SCHEMBL10622511 | 0.75 | ALDH1A1 (0.63) | ALDH1A1GLATSHRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060205980-A1 | Substituted N-sulfonylaminophenylethyl-2-phenoxyacetamide compounds as VR1 receptor antagonists | PFIZER, INC. | 2006-09-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205980-A1 | Substituted N-sulfonylaminophenylethyl-2-phenoxyacetamide compounds as VR1 receptor antagonists | CNR1, HVCN1, AVPR1A | ALDH1A1 766/4885GLA 4223/4885TSHR 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.